

**MATERIAL CHANGE REPORT  
FORM 51-102F3**

**Item 1. Name and Address**

Jolt Health Inc. (formerly Love Pharma Inc.) (the “Company”)  
1780-355 Burrard Street  
Vancouver, BC  
V6C 2C8

**Item 2. Date of Material Change**

June 2, 2023

**Item 3. News Release**

The news release describing the material change was disseminated on June 2, 2023 through GlobeNewswire and filed on SEDAR.

**Item 4. Summary of Material Change**

The Company announced that Mr. Gerald Tritt has joined the Company as a Director and CEO. Zach Stadnyk has resigned from his positions as CEO, President and as a Director of the Company.

**Item 5. Full Description of Material Change**

**5.1 *Full Description of Material Change***

The Company announced that Mr. Gerald Tritt has joined the Company as a Director and CEO. Mr. Tritt is a seasoned entrepreneur with a proven track record of success in the public markets and vast experience in various industries.

The appointment of Mr. Tritt as CEO and Director is effective immediately, and he will work closely with the Jolt Health team to develop and execute the Company’s strategic plan. Zach Stadnyk has resigned from his positions as CEO, President and as a Director of the Company.

**5.2 *Disclosure for Restructuring Transactions***

Not applicable.

**Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7. Omitted Information**

No information has been omitted in respect of this material change.

**Item 8. Executive Officer**

The following executive officer of the Company is knowledgeable about the material change disclosed in this report and may be contacted as follows:

Gerald Tritt, CEO  
Telephone: 604-671-4799

**Item 9.**

**Date of Report**

June 5, 2023.